https://www.selleckchem.com/pr....oducts/LY2603618-IC-
There are limited data on the impact of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on people with multiple sclerosis (MS). To better understand SARS-CoV-2 infection in ocrelizumab-treated people with MS. Internal Roche/Genentech data sources Cases of COVID-19 from ongoing Roche/Genentech clinical trials and from post-marketing use of ocrelizumab until July 31, 2020 were identified and assessed using descriptive statistics. External real-world data (RWD) source A
Like
Comment
Share
